Last reviewed · How we verify

GSK580299, GSK Biological's HPV vaccine

GlaxoSmithKline · Phase 3 active Biologic

GSK580299, GSK Biological's HPV vaccine is a Recombinant HPV vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of cervical cancer and precancerous lesions caused by HPV, Prevention of other HPV-related cancers (anal, oropharyngeal, vulvar, vaginal). Also known as: CervarixTM.

GSK580299 is an HPV vaccine that stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types associated with cervical cancer and other HPV-related malignancies.

GSK580299 is an HPV vaccine that stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types associated with cervical cancer and other HPV-related malignancies. Used for Prevention of cervical cancer and precancerous lesions caused by HPV, Prevention of other HPV-related cancers (anal, oropharyngeal, vulvar, vaginal).

At a glance

Generic nameGSK580299, GSK Biological's HPV vaccine
Also known asCervarixTM
SponsorGlaxoSmithKline
Drug classRecombinant HPV vaccine
TargetHuman papillomavirus (HPV) virus-like particles
ModalityBiologic
Therapeutic areaOncology / Immunology
PhasePhase 3

Mechanism of action

The vaccine contains recombinant HPV virus-like particles (VLPs) that mimic the structure of the virus without containing infectious genetic material. Upon administration, these VLPs trigger both humoral (antibody) and cell-mediated immune responses, enabling the body to recognize and eliminate HPV-infected cells before malignant transformation occurs. This preventive approach targets multiple high-risk HPV types to reduce the incidence of HPV-associated cancers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK580299, GSK Biological's HPV vaccine

What is GSK580299, GSK Biological's HPV vaccine?

GSK580299, GSK Biological's HPV vaccine is a Recombinant HPV vaccine drug developed by GlaxoSmithKline, indicated for Prevention of cervical cancer and precancerous lesions caused by HPV, Prevention of other HPV-related cancers (anal, oropharyngeal, vulvar, vaginal).

How does GSK580299, GSK Biological's HPV vaccine work?

GSK580299 is an HPV vaccine that stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types associated with cervical cancer and other HPV-related malignancies.

What is GSK580299, GSK Biological's HPV vaccine used for?

GSK580299, GSK Biological's HPV vaccine is indicated for Prevention of cervical cancer and precancerous lesions caused by HPV, Prevention of other HPV-related cancers (anal, oropharyngeal, vulvar, vaginal).

Who makes GSK580299, GSK Biological's HPV vaccine?

GSK580299, GSK Biological's HPV vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is GSK580299, GSK Biological's HPV vaccine also known as anything else?

GSK580299, GSK Biological's HPV vaccine is also known as CervarixTM.

What drug class is GSK580299, GSK Biological's HPV vaccine in?

GSK580299, GSK Biological's HPV vaccine belongs to the Recombinant HPV vaccine class. See all Recombinant HPV vaccine drugs at /class/recombinant-hpv-vaccine.

What development phase is GSK580299, GSK Biological's HPV vaccine in?

GSK580299, GSK Biological's HPV vaccine is in Phase 3.

What are the side effects of GSK580299, GSK Biological's HPV vaccine?

Common side effects of GSK580299, GSK Biological's HPV vaccine include Injection site pain or swelling, Headache, Fatigue, Myalgia, Fever.

What does GSK580299, GSK Biological's HPV vaccine target?

GSK580299, GSK Biological's HPV vaccine targets Human papillomavirus (HPV) virus-like particles and is a Recombinant HPV vaccine.

Related